Filing Summary
HUTCHMED (China) Limited filed a Form 6-K for September 2026, signed September 29, 2026. The filing identifies the company as a foreign private issuer that reports on Form 20-F.
Business Context
The exhibit index identifies a press release announcing submission of a U.S. New Drug Application for ORPATHYS® plus TAGRISSO® in MET-driven, EGFR-mutated lung cancer. The press release itself is not included in the provided filing text, so further details are unavailable here.
Financial Results and Comparisons
The provided text contains no revenue, profit, cash flow, margin, debt, liquidity, or other financial results, and no comparison with a prior period.
Outlook, Risks and Contingencies
No guidance, outlook, management commentary, risks, contingencies, or unusual financial items are described in the provided text.
Important Facts to Verify
- Review Exhibit 99.1 for the NDA submission details, supporting evidence, regulatory status, and any associated risks or timelines.
- Confirm any financial or business implications in the complete press release or other company disclosures.